[1] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016; 66, 115−32.
[2] Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin, 2023; 73, 17−48.
[3] Chen XC, Zhong FF, Li J. Trends of disease burden of pancreatic cancer attributed to high fasting plasma glucose in China, 1990-2021: insights from the global burden of disease study 2021. Biomed Environ Sci, 2025; 38, 379−84.
[4] Tao JX, Yang G, Zhou WC, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol, 2021; 14, 14.
[5] Infantino V, Santarsiero A, Convertini P, et al. Cancer cell metabolism in hypoxia: role of hif-1 as key regulator and therapeutic target. Int J Mol Sci, 2021; 22, 5703.
[6] Lin JW, Wang XJ, Zhai SY, et al. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1. J Hematol Oncol, 2022; 15, 128.
[7] Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest, 2022; 132, e159839.
[8] Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell, 2010; 40, 294−309.
[9] Yfantis A, Mylonis I, Chachami G, et al. Transcriptional response to hypoxia: the role of HIF-1-associated co-regulators. Cells, 2023; 12, 798.
[10] Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE, 2005; 2005, re12.
[11] Galbán S, Gorospe M. Factors interacting with HIF-1α mRNA: novel therapeutic targets. Curr Pharm Des, 2009; 15, 3853−60.
[12] Bao B, Ali S, Ahmad A, et al. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells Dev, 2014; 23, 1947−58.
[13] Zhao Y, Xing C, Deng YT, et al. HIF-1α signaling: essential roles in tumorigenesis and implications in targeted therapies. Genes Dis, 2024; 11, 234−51.
[14] Nevi L, Di Matteo S, Carpino G, et al. DCLK1, a putative stem cell marker in human cholangiocarcinoma. Hepatology, 2021; 73, 144−59.
[15] Yao JN, Huang XY, Sun QQ, et al. Hypoxic stimulation of DCLK1 transcription and alternative-promoter switching fuels tumor malignancy in clear cell renal cell carcinoma. Cell Death Dis, 2025; 16, 594.
[16] Ali N, Nguyen CB, Chandrakesan P, et al. Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism. Sci Rep, 2020; 10, 10578.
[17] Sureban SM, May R, Lightfoot SA, et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res, 2011; 71, 2328−38.
[18] Sureban SM, May R, Mondalek FG, et al. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnol, 2011; 9, 40.
[19] Bailey JM, Alsina J, Rasheed ZA, et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology, 2014; 146, 245−56.
[20] Westphalen CB, Takemoto Y, Tanaka T, et al. Dclk1 defines quiescent pancreatic progenitors that promote injury-induced regeneration and tumorigenesis. Cell Stem Cell, 2016; 18, 441−55.
[21] Di Giovannantonio M, Hartley F, Elshenawy B, et al. Defining hypoxia in cancer: a landmark evaluation of hypoxia gene expression signatures. Cell Genomics, 2025; 5, 100764.
[22] Moore LL, Houchen CW. Evolving insights into pancreatic tumor initiation and progression through DCLK1-expressing tuft cells. Dev Cell, 2025; 60, 817−8.
[23] Ding L, Yang YN, Ge Y, et al. Inhibition of DCLK1 with DCLK1-IN-1 suppresses renal cell carcinoma invasion and stemness and promotes cytotoxic T-cell-mediated anti-tumor immunity. Cancers, 2021; 13, 5729.
[24] Ferguson FM, Nabet B, Raghavan S, et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol, 2020; 16, 635−43.
[25] Cai J, Chen HD, Lu M, et al. Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis. Cancer Lett, 2021; 520, 1−11.
[26] Huang JJ, Lok V, Ngai CH, et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology, 2021; 160, 744−54.
[27] Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer, 2012; 12, 9−22.
[28] Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell, 2012; 148, 399−408.
[29] Westphalen CB, Quante M, Wang TC. Functional implication of Dclk1 and Dclk1-expressing cells in cancer. Small GTPases, 2017; 8, 164−71.
[30] Cao ZY, Weygant N, Chandrakesan P, et al. Tuft and cancer stem cell marker DCLK1: a new target to enhance anti-tumor immunity in the tumor microenvironment. Cancers, 2020; 12, 3801.
[31] Velázquez-Enríquez JM, Cerna R, Beltrán-Ramírez O, et al. DCLK1 is overexpressed and associated with immune cell infiltration in hepatocellular carcinoma. Biochem Genet, 2024; 62, 4280−302.